Dietary Soy/Isoflavones and Urinary Estrogen Metabolites

描述（由申请人提供）： 对大豆和异黄酮潜在抗癌作用的研究导致 美国大豆产品供应和消费的增加。 然而，相互矛盾的科学证据引起了人们的关注， 实际上可能会增加患乳腺癌的风险。目前的水平是否 大豆和大豆蛋白摄入量高到足以影响乳腺癌 风险是未知的，主要是因为缺乏方便，当前， 评估摄入量的有效方法。拟议研究的目标 是（1）评价过夜尿样作为一种方法的有效性， 评估大豆蛋白摄入量，（2）检查 大豆/大豆摄入量和尿雌激素代谢物。参与者将被 从福克斯蔡斯癌症中心的一个项目中抽取， 卵巢癌的风险这项研究将包括50名女性， 低大豆摄入量的调查问卷数据。参与者将完成 大豆食品调查问卷，并提供四个24小时尿液样本超过一个 一个月的时间内，过夜样品收集在单独的容器中。尿液 将分析大豆黄酮，主要是大豆苷元和染料木黄酮， 雌激素代谢物，包括2-、4-和16 α-羟基雌激素。异黄酮 过夜尿样中的水平将通过检查 它们与24小时尿标本中的肌酐水平的相关性。我们将 使用多元线性回归来检验大豆/大豆之间的关联 与尿中雌激素代谢物一起摄入。拟议的研究将为评估非亚洲人的大豆/大豆摄入量提供有用的信息。 sample.这也是一个机会，以增加有限的知识， 大豆/大豆摄入量及其与尿雌激素代谢物的关系， 乳腺癌风险的标志物。这项研究的结果将有助于 关于大豆补充试验的信息，以评估 大豆/豆类摄入量作为降低乳腺癌风险的一种手段， 几乎没有预防措施。

DESCRIPTION (provided by applicant): Research on potential cancer-protective effects of soy and isoflavones has led to an increase in the availability and consumption of soy products in the US. Yet conflicting scientific evidence raises the concern that high levels of intake might actually increase breast cancer risk. Whether current levels of soy and soy isoflavone intake are sufficiently high to affect breast cancer risk is unknown largely because of a lack of convenient, current, and validated methods of assessing intake. The objectives of the proposed study are to (1) evaluate the validity of overnight urine samples as a method of assessing soy isoflavone intake, and (2) examine associations between soy/isoflavone intake and urinary estrogen metabolites. Participants will be drawn from a program at Fox Chase Cancer Center for women at high breast or ovarian cancer risk. The study will include 50 women with either very high or low soy intake based on questionnaire data. Participants will complete a soyfood questionnaire and provide four 24-hour urine specimens over a one month period, with overnight samples collected in separate containers. Urines will be analyzed for isoflavones, primarily daidzein and genistein, and for estrogen metabolites including 2-, 4-, and 16alpha-hydroxy estrogens. Isoflavone levels in overnight urine samples will be evaluated for validity by examining their correlations with isoflavone levels in 24-hour urine specimens. We will use multiple linear regression to examine associations of soy/isoflavone intake with urinary estrogen metabolites. The proposed research will provide useful information towards assessment of soy/isoflavone intake in a non-Asian sample. It is also an opportunity to add to limited knowledge on soy/isoflavone intake and its association with urinary estrogen metabolites as markers of breast cancer risk. Findings from this research will contribute information towards a soy supplementation trial to evaluate modification of soy/isoflavone intake as a means of reducing risk of breast cancer, a disease for which few preventive measures are available.